Is NAD+ Therapy Worth It? An Evidence-Based Buyer Guide

"Is NAD+ therapy worth it?" is really two questions stacked on top of each other: does it work, and does it work well enough to justify what it costs you. The wellness industry answers both with a confident yes. The evidence is far more reserved — and for most healthy people shopping for energy, focus, or "anti-aging," the honest answer is that it probably isn't worth it. This is a buyer's guide, so we'll be specific about the narrow situations where the value case is least bad, and the much larger group of people who should keep their money.

First, separate "raises NAD+" from "makes you better"

Almost every claim for NAD+ therapy rests on a single, seductive logic: NAD+ (nicotinamide adenine dinucleotide) is a coenzyme central to cellular energy and DNA repair, it falls with age ¹², so topping it up should make you feel younger and more energetic. The first half is solid biology. The leap to "therefore it works" is where the value question lives — and where the trials repeatedly disappoint.

The key distinction is between raising the biomarker and improving an outcome. Human studies show NAD+ precursors reliably raise blood NAD+ in a dose-dependent way ³⁴. But raising NAD+ has repeatedly failed to deliver the benefits people are paying for: nicotinamide riboside augmented the aged-muscle NAD+ metabolome without improving muscle performance ⁵; it raised NAD+ roughly 2.6-fold without improving cognition in older adults with mild cognitive impairment ⁶; and a systematic review and meta-analysis found benefits on metabolic-syndrome parameters limited and inconsistent despite reliably higher NAD+ ⁷. You are, in effect, being sold a fuel gauge that moves while the engine output stays flat.

The IV route — the most expensive — has the least evidence

It's worth being blunt about the priciest option. NAD+ IV therapy has exactly one published human study that measured what happens inside the body, a 2019 pilot tracking the metabolome of a 6-hour infusion — and it found free NAD+ was largely undetectable in blood for hours and tested no health outcome ⁸. There is no randomized controlled trial showing IV NAD+ improves energy, focus, recovery, or aging. So when you're asking "is it worth it," the most-marketed, most-expensive route is also the one with the thinnest proof. We cover the full pricing in how much NAD+ IV therapy costs and the evidence in our NAD+ IV therapy review.

Where the value case is least bad: large, real deficits

"Worth it" is not a single answer — it depends on how far below baseline you're starting. The general principle across NAD+ biology is that restoring a large deficit plausibly does more than nudging an already-normal level, and that's where the (still weak) human signal is least absent:

• •Addiction recovery / detox. Some clinics pitch NAD+ infusions for withdrawal, and this is the one area with even descriptive human reports — small case series describing improved clinical and psychiatric measures during substance-use-disorder treatment ⁹¹⁰. But these are uncontrolled case series, not trials, and they cannot separate the drip from the surrounding rehab program. Critically, evidence-based addiction medicine — FDA-approved pharmacotherapies like buprenorphine and the medications backed by meta-analysis for alcohol use disorder — has real outcome data that NAD+ does not ¹¹¹². NAD+ should never replace that. We cover this honestly in NAD+ for addiction recovery.
• •Post-illness / chronic fatigue states. People recovering from long COVID or living with ME/CFS sometimes report benefit, and the mechanism (illness disturbing NAD+ metabolism) is plausible — but the direct human evidence is a small uncontrolled pilot, not proof. See NAD+ for long COVID and ME/CFS and NAD+ for chronic fatigue.

Even in these "least-bad" cases, the honest framing is plausible mechanism plus weak, uncontrolled human data — not proven value. If you try it, do so as an adjunct alongside evidence-based care, with clear expectations and a spending cap.

Where it's almost certainly not worth it: healthy people chasing optimization

This is the largest group of buyers, and for them the value case is weakest. If you're a healthy adult seeking more energy, sharper focus, better workouts, or "anti-aging," you are paying premium prices to raise a biomarker that, in controlled trials, did not reliably translate into any of those felt benefits ⁵⁶⁷. No NAD+ therapy has been shown to extend human lifespan or reverse aging — see is NAD+ really anti-aging — and the "instant energy" pitch isn't backed by the precursor trials either, as we detail in does NAD+ actually boost energy.

The cost reality that decides "worth it"

Value is benefit divided by cost, and the cost side is steep. NAD+ IV drips run roughly $250–$1,500 a session and $1,500–$6,000 for a typical package, never covered by insurance — full numbers in how much NAD+ IV therapy costs. By contrast, the oral precursors that actually have human trials showing they raise NAD+ cost about $20–$40 a month ³⁴. So even on its own terms, the "is it worth it" calculation is lopsided: the expensive route has no outcome evidence, and the cheap route — while it reliably raises the biomarker — still hasn't been shown to reliably improve how people feel (see does NMN actually work). For how the injectable route compares, see NAD+ injections: what the research shows.

Who should skip it

• •Healthy adults chasing energy, focus, or anti-aging — the trials don't support paying for it.
• •Anyone expecting an IV to outperform cheaper oral precursors — there's no head-to-head evidence it does.
• •Anyone considering it as a substitute for medical treatment — especially for addiction, where proven medications exist ¹¹¹².
• •Anyone on a tight budget — the recurring "maintenance" model can run into thousands a year for an unproven service.

The bottom line

For most people, NAD+ therapy is not worth it: the most-marketed route (IV) has a single pharmacokinetic pilot and no outcome trials ⁸, the cheaper precursor routes raise NAD+ without reliably improving outcomes ⁵⁶⁷, and the price — especially for recurring infusions — is high. The value case is least bad for people starting from a large, real deficit (addiction recovery, post-illness fatigue), and even there the human data is weak and uncontrolled, so NAD+ belongs as an adjunct to evidence-based care, never a replacement. Before spending, read our NAD+ therapy evidence pillar, see the cost breakdown in how much NAD+ IV therapy costs, and check vetted options on our NAD+ rankings hub.